Search

Displaying results 2871 - 2880 of 9132 in total
  1. Drug

    Taletrectinib

    go.drugbank.com/drugs/DB18711
    ApprovedInvestigational

    [L53308] Gene fusions involving _ROS1_, a proto-oncogene, have been identified as oncogenic drivers in 1-2% of patients with non-small cell lung cancer (NSCLC), in addition to other cancers at variable … Taletrectinib is an orally available small molecule kinase inhibitor.

  2. Drug

    Varespladib methyl

    go.drugbank.com/drugs/DB05737
    Investigational

    Varespladib methyl has been investigated for the treatment of Acute Coronary Syndrome. Studies showed that Varespladib methyl treatment resulted in significant positive changes on lipoproteins and inflammation.

    Categories: Phospholipase A2 Inhibitors
  3. Drug

    Siponimod

    go.drugbank.com/drugs/DB12371
    ApprovedInvestigational

    Siponimod, also known as _Mayzent_, by Novartis, is a new drug formulated for the management of Multiple Sclerosis (MS). … [L12171] This drug is considered a _sphingosine-1-phosphate (S1P) receptor modulator_ and is thought to play a role in suppressing the central nervous system inflammation that is associated with MS [FDA

    Categories: Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
  4. Drug

    Indacaterol

    go.drugbank.com/drugs/DB05039
    ApprovedInvestigational

    It is marketed in Europe as Onbrez and in America as Arcapta Neohaler. Indacaterol is provided as its maleate salt form. … Indacaterol is also a chiral molecule but only the pure R-enantiomer is dispensed.

  5. Drug

    Tridolgosir

    go.drugbank.com/drugs/DB02034
    Experimental

    An indolizidine alkaloid from the plant Swainsona canescens that is a potent alpha-mannosidase inhibitor. Swainsonine also exhibits antimetastatic, antiproliferative, and immunomodulatory activity.

  6. Drug

    iCo-007

    go.drugbank.com/drugs/DB05268
    Investigational

    ) such as age-related macular degeneration (AMD) and diabetic retinopathy(DR). … iCo-007 (formerly known as ISIS 13650) is a second generation antisense compound being developed by iCo for the treatment of various eye diseases caused by the formation of new blood vessels (angiogenesis

  7. Drug

    Golodirsen

    go.drugbank.com/drugs/DB15593
    ApprovedInvestigational

    [A188580,T756] A similar drug used in the treatment of other types of DMD is [eteplirsen], which targets a different genetic mutation. … Golodirsen is a morpholino antisense oligomer designed to treat about 8% of patients with Duchenne Muscular Dystrophy (DMD).

    Categories: Compounds used in a research, industrial, or household setting
  8. Drug

    Erythropoietin

    go.drugbank.com/drugs/DB00016
    ApprovedInvestigational

    various clinical conditions, such as chronic renal failure, antiviral drug therapy, chemotherapy, or a high risk for perioperative blood loss from surgical procedures [FDA Label]. … The biosimilar is approved by the FDA and EMA as a safe, effective and affordable biological product and displays equivalent clinical efficacy, potency, and purity to the reference product [A7504].

    Products: EXETIN-A, EPO STADA 2000IU/0.6ml Solution for Injection in a Pre-filled Syringe
  9. Drug

    Chlorophetanol

    go.drugbank.com/drugs/DB11368
    Experimental

    Chlorophetanol is an agent known to have antifungal activities.

  10. Drug

    Ferric oxyhydroxide

    go.drugbank.com/drugs/DB14695
    Experimental

    An antiferromagnetic material; constitutes the core of natural ferritin.